Profile data is unavailable for this security.
About the company
Aspen Pharmacare Holdings Limited is a South Africa-based global specialty and branded multinational pharmaceutical company. The Company focuses on marketing and manufacturing a range of post-patent, branded medicines and domestic brands covering both hospital and consumer markets. Its segments include Prescription, Over the counter (OTC), Injectables, Active Pharmaceutical Ingredients (API), Finished Dose Form (FDF) and Heparin. It offers sterile products in injectable form primarily administered in hospitals and also those prescribed and administered by either physicians or in a retail pharmacy environment. Its key brands include Arixtra, Diprivan, Fraxiparine, Marcaine, Sustanon and Xylocaine (Injectables). Its OTC segment includes products that do not require prescriptions and are primarily sold in the retail pharmacy and fast-moving consumer goods sectors. Its Prescription segment includes products which generally require a prescription from a healthcare professional.
- Revenue in ZAR (TTM)44.71bn
- Net income in ZAR4.40bn
- Incorporated1985
- Employees8.87k
- LocationAspen Pharmacare Holdings LtdAspen Place, 9 Rydall Vale ParkDouglas Saunders Drive ,La Lucia RidgeLA LUCIA South AfricaZAF
- Phone+27 315808600
- Fax+27 112396111
- Websitehttp://www.aspenpharma.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Laboratorios Farmaceuticos ROVI SA | 14.83bn | 2.82bn | 75.91bn | 2.14k | 27.53 | 8.46 | 23.10 | 5.12 | 2.82 | 2.82 | 14.89 | 9.19 | 0.8855 | 0.8691 | 5.92 | 368,545.70 | 16.84 | 18.90 | 25.66 | 25.58 | 60.52 | 59.82 | 19.02 | 20.13 | 0.6801 | 313.46 | 0.2006 | 34.37 | 1.44 | 22.30 | -14.69 | 56.93 | 15.84 | 69.11 |
| Organon & Co | 112.34bn | 22.81bn | 76.36bn | 10.00k | 3.36 | 8.84 | 2.79 | 0.6797 | 5.04 | 5.04 | 24.81 | 1.91 | 0.5394 | 2.08 | 3.85 | 640,900.00 | 10.95 | 16.53 | 14.08 | 20.97 | 58.26 | 65.12 | 20.30 | 26.79 | 1.21 | 2.73 | 0.9467 | 8.25 | 1.44 | -8.52 | 11.56 | -13.83 | 20.91 | -- |
| Bluestar Adisseo Co | 36.90bn | 2.69bn | 76.48bn | 2.73k | 28.42 | 1.96 | -- | 2.07 | 0.4064 | 0.4064 | 5.57 | 5.90 | 0.6887 | 5.18 | 8.01 | 5,466,479.00 | 5.03 | 5.28 | 6.07 | 6.94 | 29.20 | 30.31 | 7.30 | 8.76 | 1.16 | 7.83 | 0.1105 | 21.81 | -9.26 | 2.92 | -95.82 | -43.75 | 2.74 | -19.09 |
| Ajanta Pharma Ltd | 9.36bn | 1.82bn | 77.67bn | 7.84k | 42.91 | 10.14 | 36.84 | 8.30 | 69.55 | 69.55 | 356.94 | 294.36 | 0.9738 | 1.33 | 4.16 | 5,725,128.00 | 18.97 | 16.61 | 23.29 | 20.47 | 75.77 | 73.22 | 19.48 | 19.31 | 2.13 | 49.88 | 0.0088 | 31.20 | 12.45 | 15.41 | 38.81 | 16.10 | -14.97 | 10.76 |
| ADMA Biologics Inc | 5.79bn | 609.81m | 78.08bn | 624.00 | 135.91 | 23.65 | 103.22 | 13.49 | 0.1406 | 0.1406 | 1.41 | 0.8079 | 0.9181 | 1.04 | 9.88 | 529,237.60 | 9.67 | -24.80 | 10.99 | -28.00 | 46.12 | 17.40 | 10.53 | -51.31 | 2.80 | 4.59 | 0.4105 | -- | 67.59 | 72.34 | 57.15 | -- | 18.91 | -- |
| Xiamen Amoytop Biotech Co Ltd | 6.41bn | 1.83bn | 78.22bn | 1.96k | 42.77 | 13.99 | -- | 12.21 | 1.82 | 1.82 | 6.38 | 5.57 | 1.08 | 0.8928 | 6.18 | 1,324,099.00 | 30.73 | 17.96 | 35.90 | 21.02 | 92.71 | 90.48 | 28.54 | 19.17 | 3.60 | -- | 0.0044 | 26.95 | 37.55 | 36.19 | 93.52 | 103.28 | 81.61 | -- |
| China Resources Pharmaceutical Group Ltd | 617.07bn | 9.30bn | 79.63bn | 72.76k | 8.56 | 0.6685 | 2.80 | 0.129 | 0.6562 | 0.6562 | 43.55 | 8.41 | 0.966 | 6.09 | 3.28 | 3,748,829.00 | 3.19 | 3.02 | 12.13 | 11.35 | 15.78 | 15.72 | 3.31 | 2.87 | 1.12 | 11.50 | 0.4396 | 24.73 | 12.16 | 8.86 | 10.11 | 2.80 | 13.58 | 7.05 |
| Aspen Pharmacare Holdings Limited | 44.71bn | 4.40bn | 80.70bn | 8.87k | 18.24 | 0.9467 | 12.66 | 1.81 | 9.91 | 9.91 | 100.64 | 191.03 | 0.327 | 1.34 | 3.48 | 5,041,841.00 | 3.22 | 3.92 | 3.90 | 4.90 | 43.52 | 46.88 | 9.85 | 12.43 | 1.07 | 7.93 | 0.3005 | 23.46 | 9.82 | 4.71 | -15.76 | 21.27 | 9.09 | -- |
| Kalbe Farma Tbk PT | 35.75bn | 3.43bn | 82.94bn | 12.92k | 23.82 | 3.31 | 19.29 | 2.32 | 66.76 | 66.76 | 696.65 | 480.69 | 1.15 | 2.93 | 6.43 | 2,450,938,000.00 | 11.09 | 12.50 | 14.03 | 15.48 | 37.46 | 41.21 | 9.65 | 11.26 | 2.56 | -- | 0.0302 | 50.53 | 5.24 | 7.64 | -18.20 | 2.40 | -3.00 | 3.58 |
| BridgeBio Pharma Inc | 3.84bn | -7.96bn | 83.06bn | 550.00 | -- | -- | -- | 21.62 | -2.64 | -2.64 | 1.24 | -5.81 | 0.3376 | -- | -- | 398,407.30 | -71.11 | -72.44 | -89.59 | -89.72 | 98.91 | 94.41 | -210.62 | -1,225.66 | -- | -9.63 | 2.70 | -- | -88.02 | -- | -33.67 | -- | -40.94 | -- |
| ALK-Abello A/S | 13.24bn | 1.76bn | 83.75bn | 2.81k | 52.29 | 7.28 | 32.95 | 6.32 | 3.09 | 3.09 | 22.91 | 22.22 | 0.7673 | 1.27 | 6.11 | 1,834,278.00 | 10.22 | 3.50 | 12.56 | 4.37 | 63.42 | 60.66 | 13.32 | 5.07 | 1.29 | 479.50 | 0.0934 | 0.00 | 6.94 | 10.60 | 45.07 | -- | 16.32 | -- |
| IPCA Laboratories Ltd | 17.11bn | 1.20bn | 83.79bn | 17.34k | 69.73 | -- | 42.39 | 4.90 | 22.74 | 22.74 | 323.71 | -- | -- | -- | -- | 4,737,502.00 | -- | 10.33 | -- | 13.52 | 67.08 | 59.16 | 6.84 | 12.25 | -- | 15.41 | -- | 12.86 | 23.39 | 15.35 | 16.13 | 4.24 | 17.90 | 21.67 |
| Krka d.d. Novo Mesto | 35.68bn | 6.98bn | 85.04bn | 11.79k | 11.48 | 1.75 | 9.62 | 2.38 | 11.85 | 11.85 | 60.59 | 77.51 | 0.6476 | 1.40 | 3.59 | 160,399.30 | 12.64 | 12.64 | 14.86 | 15.12 | 56.10 | 57.29 | 19.52 | 18.71 | 3.04 | -- | 0.005 | 59.21 | 5.18 | 6.28 | -13.58 | 12.45 | 8.35 | 18.57 |
| Humanwell Healthcare Group Co Ltd | 63.10bn | 4.83bn | 85.32bn | 17.68k | 17.47 | 1.93 | -- | 1.35 | 1.21 | 1.21 | 15.87 | 10.95 | 0.6902 | 3.80 | 2.74 | 1,445,825.00 | 7.13 | 6.20 | 13.12 | 12.72 | 45.59 | 42.82 | 10.33 | 9.84 | 1.21 | 12.09 | 0.3171 | 18.87 | 9.79 | 5.65 | -14.07 | -- | 8.25 | -- |
Data as of Nov 05 2024. Currency figures normalised to Aspen Pharmacare Holdings Ltd's reporting currency: South African Rand ZAR
41.27%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| Public Investment Corporation (SOC) Ltd.as of 02 Feb 2024 | 90.00m | 20.17% |
| Coronation Asset Management (Pty) Ltd.as of 30 Jun 2023 | 24.55m | 5.50% |
| The Vanguard Group, Inc.as of 02 Oct 2024 | 14.09m | 3.16% |
| Capital Research & Management Co. (World Investors)as of 03 Oct 2024 | 13.31m | 2.98% |
| Foord Asset Management Pty Ltd.as of 30 Jun 2023 | 10.78m | 2.42% |
| BlackRock Fund Advisorsas of 03 Oct 2024 | 7.12m | 1.60% |
| Schroder Investment Management Ltd.as of 30 Sep 2024 | 6.73m | 1.51% |
| Old Mutual Customised Solutions (Pty) Ltd.as of 30 Jun 2023 | 6.54m | 1.47% |
| GIC Pte Ltd. (Investment Management)as of 30 Jun 2023 | 5.95m | 1.33% |
| Old Mutual Life Assurance Co. (South Africa) Ltd.as of 30 Jun 2023 | 5.09m | 1.14% |
More ▼
Data from 31 Mar 2023 - 31 Oct 2024Source: FactSet Research Systems Inc.
